Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer To Use Cash From Sale Of OTC Unit To J&J For Biotech, Specialty Deals

Executive Summary

Pfizer will use the cash gained through the sale of its consumer unit to Johnson & Johnson to make targeted specialty pharma and biotech acquisitions, the firm said following announcement of the deal June 26

You may also be interested in...



J&J Acquisitions Governed By Payback Potential, Despite Credit “Uncertainty”

Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call

J&J Acquisitions Governed By Payback Potential, Despite Credit “Uncertainty”

Maintaining a stellar credit rating is not a constraint on how much Johnson & Johnson is willing to spend on acquisitions, Chief Financial Officer Dominic Caruso said during the company's April 15 first quarter earnings call

Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys

Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel